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ABSTRACT
Objective: To characterise the trends in the left
ventricular assist device (LVAD) implantation rates and
outcomes between 2004 and 2011 in the Medicare
population. Since the approval of the HeartMate II in
2008, the use of LVADs has steadily climbed. Given the
increase in LVAD use, issues around discharge
disposition, post-implant hospitalisations and costs
require further understanding.
Methods: We examined LVAD implantation rates and
short-term and long-term outcomes among Medicare
fee-for-service beneficiaries hospitalised for LVAD
implantation. We also conducted analyses among
survivors 1-year post-discharge to examine
rehospitalisation rates. Lastly, we reported Centers for
Medicare & Medicaid Services (CMS) payments for both
index hospitalisation and rehospitalisations 1 year post-
discharge.
Results: A total of 2152 LVAD implantations were
performed with numbers increasing from 107 in 2004 to
612 in 2011. The 30-day mortality rate decreased from
52% to 9%, and 1-year mortality rate decreased from
69% to 31%. We observed no change in overall length of
stay, but post-procedure length of stay increased. We
also found an increase in home discharge dispositions
from 26% to 53%. Between 2004 and 2010, the
rehospitalisation rate increased and the number of
hospital days decreased. The adjusted CMS payment for
the index hospitalisation increased from $188 789 to
$225 697 over time but decreased for rehospitalisation
from $60 647 to $53 630.
Conclusions: LVAD implantations increased over time.
We found decreasing 30-day and 1-year mortality rates
and increasing home discharge disposition. The
proportion of patients rehospitalised among 1-year
survivors remained high with increasing index
hospitalisation cost, but decreasing post-implantation
costs over time.
INTRODUCTION
Over the last decade, since the publication of
the Randomised Evaluation of Mechanical
Assistance in the Treatment of Congestive
Heart Failure (REMATCH) trial in 2001,
1 left
ventricular assist devices (LVADs) have become
an established life-saving therapeutic option in
the treatment of elderly patients with end-stage
heart failure, who are often ineligible for heart
transplant. After the release of the REMATCH
trial results, in 2002 the USA Food and Drug
Administration (FDA) approved the use of
LVADs as destination therapy.
2 This was fol-
lowed by the decision from the Centers for
Medicare & Medicaid Services (CMS) to pay
for LVADs as destination therapy.
3 Further, in
2005 the American College of Cardiology/
American Heart Association guidelines
expanded the use of LVADs to include ‘highly
selected patients with refractory end-stage
heart failure with estimated survival of <50% at
one year’(Level of Evidence: B).
4 However,
large device size, high cost and device-related
complications limited the use of LVADs at that
time.
5–7 Despite these challenges, Hernandez
et al
8 reported that LVAD implantation rates
were increasing among Medicare beneﬁciaries
from 2000 to 2006.
A new generation of much smaller devices
with less morbidity came with the FDA
approval of the HeartMate II in 2008, which
demonstrated 1-year survival rates up to
85%.
9–11 Khazanie et al
12 described a contin-
ued increase in LVAD implantations after
KEY MESSAGES
What is already known about this subject?
▸ LVADs are a life-saving therapy whose use is
increasing over time.
What does this study add?
▸ Most patients are alive one year after LVAD
placement with increasing costs for the proced-
ure. Although many patients are discharged to
home, rehospitalisation rates remain high.
How might this impact on clinical practice?
▸ These trends in mortality, rehospitalisation and
cost of LVAD implantation merit consideration
by patients, physicians, and policy makers.
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Heart failure and cardiomyopathies2006 and reported stable cost of LVADs over time. Given
the increase in LVAD use, issues around discharge dis-
position, post-implant hospitalisations and costs require
further understanding. Accordingly, we used data from
all Medicare fee-for-service beneﬁciaries 65 years or
older to determine the current trends in device utilisa-
tion, short-term outcomes, long-term outcomes, dis-
charge disposition and costs for LVADs.
METHODS
Data sources and coding
In the USA, CMS is an agency within the US
Department of Health & Human Services responsible
for administration of several key federal healthcare pro-
grammes including Medicare. Medicare is the federal
health insurance for patients older than 65 years, or
patients with disabilities or end-stage renal disease.
Medicare fee-for-service is a programme that provides
hospital insurance (Part A) and supplementary medical
insurance (Part B) to eligible residents.
13 In this study,
we used inpatient National Claims History ﬁles from
CMS to identify all Medicare fee-for-service beneﬁciaries
who were hospitalised for LVAD placement between 1
January 2004 and 31 December 2011. The administrative
claims included information on patient demographics
(age, sex and race), admission, procedure, discharge
dates, discharge disposition, discharge diagnosis and
procedure codes (as coded by the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM)). We deﬁned LVAD implanta-
tions as hospital discharges that included the ICD-9-CM
procedure code for LVAD implantation (37.66). To
isolate LVADs placed for long-term therapy, we excluded
codes 37.62, 37.65 and 37.68 used for temporary non-
implantable, or external or percutaneous external assist
devices. We obtained corresponding Medicare denomin-
ator ﬁles from 2004 to 2011, which contained informa-
tion on patients’ eligibility and enrolment in Medicare,
and mortality information, including both in-hospital
and non-hospital deaths. We used the 2003 ﬁle as a base-
line ﬁle to determine beneﬁciaries’ length of
fee-for-service status in 2004. We included all beneﬁciar-
ies aged 65 years and older who resided in the USA. For
1-year outcomes, the 2011 data were used as a follow-up
for 2010 and the analyses were restricted from 2004 to
2010.
Patient characteristics and comorbidities
We reported patient characteristics yearly over the study
period. We examined the clinical characteristics of
patients admitted for LVAD implantation across years
and stratiﬁed by age (65–74 and 75 years or older), sex,
and race (white, black and other). We determined race
from the Medicare denominator ﬁle, which used
patient-reported data from the Social Security
Administration.
14 We identiﬁed comorbidities from sec-
ondary diagnosis codes of the index hospitalisation for
LVAD surgery and principal or secondary diagnosis
codes of hospitalisations up to 1 year before the index
hospitalisation. This method and corresponding diagno-
sis codes have been used for proﬁling hospitals by the
CMS 30-day mortality measures for acute myocardial
infarction,
15 heart failure
15 and pneumonia.
16 We used
the 2003 data as a baseline ﬁle to determine patients’
comorbidities in 2004.
LVAD implantation rates and mortality
For each year, we calculated the LVAD implantation rate
by dividing the number of LVAD implantation proce-
dures performed (numerator) by the total accumulated
person-years of Medicare fee-for-service beneﬁciaries for
that year (denominator). We calculated person-years for
each beneﬁciary to account for new enrolment, disenrol-
ment or death during an index year. To calculate
in-hospital, 30-day, and 1-year mortality, we identiﬁed all
LVAD implantations that occurred in a given year. If a
patient had more than one LVAD implantation in a
given year, an implantation was randomly selected. The
procedure date for the LVAD surgery represented the
‘time zero’ for the mortality analysis. We conducted sen-
sitivity analyses comparing age-sex-race mortality models
with age-sex-race-comorbidity models to assess the poten-
tial inﬂuence of changing comorbidity coding patterns
on trends in risk-adjusted mortality.
Length of stay, discharge disposition and 30-day
readmission rates for index hospitalisation
We calculated hospital length of stay (LOS) as the differ-
ence between the discharge and admission dates. We
deﬁned pre-LOS as the date from admission to the date
of LVAD implantation minus 1 and post-LOS as the date
from the day of the procedure to the date of discharge.
We deﬁned 30-day readmission as all-cause readmis-
sion to an acute-care hospital within 30 days of discharge
from the index LVAD surgery. This strategy is consistent
with that used for CMS publicly reported measures.
17–19
Major discharge dispositions included discharge to
home; to home with in-home healthcare, and to a
skilled nursing facility or intermediate care facility.
Rehospitalisations among 1-year survivors
Using the patient identiﬁer, we calculated the number
of patients surviving 1 year after LVAD implantation who
were rehospitalised within 1 year. Rehospitalisation rate
was deﬁned as the total number of all-cause rehospitali-
sations to an acute-care facility within 1 year from the
discharge of the index hospitalisation divided by the
total number of 1-year survivors. Rehospitalisation dur-
ation was deﬁned as the mean number of days spent in
the hospital per patient within 1 year.
CMS payments
The CMS payment for the index hospitalisation was
deﬁned as the total payment made from CMS for the
LVAD implantation hospitalisation. The CMS payment
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Open Heartfor rehospitalisations was deﬁned as the total payment
made per living LVAD patient for all rehospitalisations
within 1 year after the index discharge. We adjusted all
dollar amounts for the index stay to 2011 values by
applying the CMS Market Basket update for the
inpatient hospital prospective payment system (operating
only). We adjusted all dollar amounts for the rehospitali-
sation analysis to 2010 dollars using the same inﬂation
factor.
Statistical analysis
We reported LVAD implantation rates per 1 million
person-years. We expressed mortality, readmission and
major discharge disposition as percentages. We
expressed LOS as mean (SD) days. We used the
Mantel-Haenszel χ
2 test to analyse whether changes over
time in the outcomes were statistically signiﬁcant.
To estimate the annual change in LVAD implantation
over time, we ﬁtted a linear mixed effects model with a
Poisson link function and state-speciﬁc random inter-
cepts, and adjusted for demographics (age, sex and
race). Risk-adjustment models were developed for a
broader population of hospitalised Medicare patients
with heart failure rather than this speciﬁc cohort who
received LVADs.
15 For this analysis, we modelled time by
using 2004 as a reference and including seven indicator
variables for the subsequent years in the model. The
estimate of the indicator variables represents
the risk-adjusted change in LVAD implantation rates in
the index year, compared with 2004. To estimate the
national trends of in-hospital, 30-day and 1-year mortal-
ity, we ﬁtted a linear mixed effects model with a logit
link function and hospital-speciﬁc random intercepts,
adjusting for patient covariates from previously validated
mortality models including age, sex, race, 14 comorbid-
ities available from administrative coding and a continu-
ous time variable, ranging from 0 to 7, representing
2004 to 2011 (2010 for 1-year mortality). For 30-day all-
cause readmission rates, we constructed a Cox propor-
tional model with hospital-speciﬁc random intercepts
and the time variable, adjusting for patient demograph-
ics and comorbidities. A 95% CI was also calculated for
each point estimate from the models. A p value of <0.05
(two-sided test) was considered statistically signiﬁcant.
All analyses were conducted using SAS V.9.3, 64-bit
Windows version (SAS Institute Inc, Cary, North
Carolina, USA).
We obtained Institutional Review Board approval
through the Yale University Human Investigation
Committee, which waived the requirement for informed
consent. Conﬁdential data were protected through a
data use agreement with CMS.
RESULTS
Patient characteristics and LVAD implantations
The ﬁnal sample consisted of 236 624 284 observations
in the denominator ﬁles, representing 33 952 331
unique individual Medicare fee-for-service beneﬁciaries
who contributed to 225 292 512 person-years of observa-
tion from 2004 to 2011. The mean age of patients
undergoing LVAD was stable at 71 years (p=0.3 for
trend). Several comorbidities were more commonly
coded in LVAD recipients over time, including renal
failure (17.8–54.2%, p<0.001), respiratory failure (8.4–
23.5%, p<0.0056) and malnutrition (3.7–26.3%,
p<0.001) (table 1).
There were 2152 LVAD implantations performed
during the 8-year period, and the number of implanta-
tions increased from 107 (3.7/1 million person-years) in
2004 to 612 (21.9/1 million person-years) in 2011, a
relative increase of 491.0% (ﬁgure 1). Through 2009,
only 108 (9.0%) of the LVAD recipients included in our
cohort received heart transplantation within 1 year after
LVAD placement. Over time, LVAD implantation
increased more among patients aged 65–74 years than
among patients ≥75 years, although a substantial
increase was also seen in this latter group with 103
patients over 75 years who received an LVAD in 2011
compared to 19 patients in 2004. In all years, men
received more LVADs than women. In 2011, 517 (42.4/1
million person-years) and 95 (6.0/1 million person-
years) LVADs were implanted in men and women,
respectively (table 2). Moreover, LVAD implantations
increased the most among black patients (704.0%) com-
pared to whites over time.
Changes in mortality and readmission rates among LVAD
recipients
There were substantial declines in in-hospital (57.9–
6.0%), 30-day (52.3–9.0%) from 2004 to 2011 and in
1-year mortality rates (69.2–31.2%) from 2004 to 2010,
all p values <0.01 for linear trends, despite ﬂuctuations
throughout the study period. In the subgroup analysis,
we found the steepest declines in unadjusted in-hospital
mortality rates among women (69.2–21.1%) and whites
(56.3–15.7%). Declines in 30-day mortality rates were
also seen across all subgroups with the most dramatic
declines among the following: patients aged ≥75 years
(69.2–3.3%), women (61.5–12.6%) and non-whites, non-
blacks (80.0–17.2%). The steepest declines in
unadjusted 1-year mortality rates were noted in a similar
proﬁle of subgroups (table 3). After adjusting for demo-
graphics and comorbidities, the annual change in
in-hospital, 30-day and 1-year mortality rates remained
statistically signiﬁcant (OR=0.73, 95% CI 0.69 to 0.78;
OR=0.75, 95% CI 0.71 to 0.79; OR=0.86, 95% CI 0.79 to
0.94, respectively; ﬁgure 2).
There was a 22.0% relative decrease in the unadjusted
30-day readmission rate (38.1–29.7%) over time.
Additional changes were noted in the subgroup analysis
by race, with black patients presenting the most dramatic
decrease (51.3% relative decrease) in readmission over
time. After risk-adjustment, the overall 30-day readmis-
sion rate was not statistically signiﬁcant (relative
risk=0.97, 95% CI 0.91 to 1.03) (ﬁgure 2).
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2004 2005 2006 2007 2008 2009 2010 2011 p Value*
Patients undergoing LVAD, n 107 181 133 185 206 295 433 612 <0.0001
Age, mean (SD), years 71.2 (4.2) 70.9 (4.1) 71.4 (4.5) 71.2 (4.4) 70.5 (4.0) 70.5 (4.2) 70.8 (4.0) 71.1 (4.4) 0.3128
Female, n (%) 26 (24.3) 45 (24.9) 27 (20.3) 32 (17.3) 42 (20.4) 35 (11.9) 59 (13.6) 95 (15.5) <0.0001
White, n (%) 96 (89.7) 156 (86.2) 111 (83.5) 154 (83.2) 182 (88.3) 255 (86.4) 383 (88.5) 536 (87.6) 0.7265
Black, n (%) 6 (5.6) 13 (7.2) 14 (10.5) 18 (9.7) 15 (7.3) 24 (8.1) 34 (7.9) 47 (7.7)
Other†, n (%) 5 (4.7) 12 (6.6) 8 (6.0) 13 (7.0) 9 (4.4) 16 (5.4) 16 (3.7) 29 (4.7)
Cardiovascular conditions and risk factors
Coronary artery disease, n (%) 77 (72.0) 107 (59.1) 79 (59.4) 110 (59.5) 145 (70.4) 210 (71.2) 300 (69.3) 427 (69.8) 0.0172
Prior heart failure, n (%) 57 (53.3) 106 (58.6) 77 (57.9) 120 (64.9) 144 (69.9) 219 (74.2) 330 (76.2) 478 (78.1) <0.0001
Prior myocardial infarction, n (%) 7 (6.5) 22 (12.2) 11 (8.3) 18 (9.7) 22 (10.7) 29 (9.8) 40 (9.2) 58 (9.5) 0.9912
Unstable angina, n (%) 7 (6.5) 11 (6.1) 5 (3.8) 7 (3.8) 17 (8.3) 23 (7.8) 20 (4.6) 50 (8.2) 0.9889
Peripheral vascular disease, n (%) 12 (11.2) 15 (8.3) 14 (10.5) 20 (10.8) 24 (11.7) 39 (13.2) 49 (11.3) 65 (10.6) 0.3024
Hypertension, n (%) 54 (50.5) 79 (43.6) 42 (31.6) 76 (41.1) 107 (51.9) 160 (54.2) 242 (55.9) 354 (57.8) <0.0001
Diabetes, n (%) 33 (30.8) 59 (32.6) 34 (25.6) 53 (28.6) 68 (33.0) 106 (35.9) 164 (37.9) 234 (38.2) 0.0126
Geriatric conditions
Malnutrition, n (%) 4 (3.7) 25 (13.8) 12 (9.0) 31 (16.8) 31 (15.0) 63 (21.4) 100 (23.1) 161 (26.3) <0.0001
Other conditions
COPD, n (%) 24 (22.4) 48 (26.5) 31 (23.3) 53 (28.6) 51 (24.8) 66 (22.4) 83 (19.2) 129 (21.1) 0.0559
Pneumonia, n (%) 11 (10.3) 32 (17.7) 12 (9.0) 38 (20.5) 40 (19.4) 60 (20.3) 83 (19.2) 139 (22.7) 0.0176
Respiratory failure, n (%) 9 (8.4) 23 (12.7) 14 (10.5) 33 (17.8) 43 (20.9) 59 (20.0) 72 (16.6) 144 (23.5) 0.0056
Renal failure, n (%) 19 (17.8) 47 (26.0) 51 (38.3) 66 (35.7) 88 (42.7) 142 (48.1) 220 (50.8) 332 (54.2) <0.0001
Cancer, n (%) 5 (4.7) 11 (6.1) 9 (6.8) 12 (6.5) 10 (4.9) 17 (5.8) 26 (6.0) 43 (7.0) 0.9452
Trauma in past year, n (%) 6 (5.6) 7 (3.9) 5 (3.8) 9 (4.9) 13 (6.3) 16 (5.4) 25 (5.8) 28 (4.6) 0.3648
*p Value based on Mantel–Haenszel χ
2 test.
†Includes Asian, Hispanic, North American Native or other not specified.
COPD, chronic obstructive pulmonary disease; LVAD, left ventricular assist device.
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No signiﬁcant changes were noted for the overall LOS
(23.6 days in 2004–27.3 days in 2011). Pre-LOS changed
from 11.4 to 8.7 days and with mean post-LOS rising
from 12.2 to 18.6 days, a relative increase of 52.4%
(table 3).
The percentage of patients discharged home without
home care increased from 12.1% to 18.0% over time;
while the percentage of patients discharged with home
care increased from 14.0% in 2004 to 34.8% in 2011
(table 3). The number of patients discharged to home
or to home with home care showed a relative increase of
48.7% and 148.5%, respectively.
Rehospitalisation-related outcomes
The number of patients alive 1 year after LVAD implant-
ation increased from 45 (42.0%) in 2004 to 348 (80.0%)
in 2010 whereas the proportion of survivors that were
rehospitalised within 1 year increased from 70.0% to
80.0% (p<0.01). The mean number of rehospitalisations
per patient showed a 28.0% relative increase from 2004
compared to 2010. The ﬁve most frequent reasons for
rehospitalisations were complications related to the pro-
cedure (31.9%) followed by heart failure (23.0%),
cardiac dysrhythmias (14.7%), gastrointestinal haemor-
rhage (14.7%) and other disorders of the intestine
(12.1%). Among patients rehospitalised the overall
mean days spent in hospital per patient decreased from
30.2 days in 2004 to 20.8 days in 2010 (p<0.01).
CMS payments
The total CMS payment for the index hospitalisation per
patient increased from $188 789 to $225 697 whereas
the payment for all rehospitalisations in the ﬁrst year
after implantation decreased from $60 647 to $53 630,
from 2004 to 2010. The average annual change for
index hospitalisations was 2.8% from 2004 to 2011 and
for rehospitalisations was 4.6% from 2004 to 2010. For
Figure 1 Trends in LVAD implantation rates among the
Medicare population from 2004 to 2011. Rates of LVAD
implantation were calculated as numbers of LVAD procedures
per 1 million person-years. Grey area: 95% confidence limits;
diamond: observed values; solid line: growth trend over time;
p=0.0395. LVAD, left ventricular assist device.
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Heart failure and cardiomyopathiesTable 3 Outcomes among patients undergoing LVAD in Medicare fee-for-service, 2004–2011
2004 2005 2006 2007 2008 2009 2010 2011
In-hospital mortality rate, n (%) 62 (57.9) 93 (51.4) 56 (42.1) 61 (33.0) 58 (28.2) 60 (20.3) 85 (19.6) 98 (16.0)
By age group
65–74, n (%) 42 (51.9) 79 (53.0) 41 (39.0) 41 (30.1) 47 (27.3) 48 (20.3) 62 (17.8) 76 (15.7)
≥75, n (%) 20 (76.9) 13 (41.9) 15 (53.6) 19 (39.6) 11 (33.3) 12 (20.7) 22 (26.2) 20 (16.4)
By gender
Female, n (%) 18 (69.2) 30 (66.7) 11 (40.7) 13 (40.6) 11 (26.2) 5 (14.3) 11 (18.6) 20 (21.1)
Male, n (%) 44 (54.3) 63 (46.3) 45 (42.5) 48 (31.4) 47 (28.7) 55 (21.2) 74 (19.8) 78 (15.1)
By race
White, n (%) 54 (56.3) 83 (53.2) 46 (41.4) 49 (31.8) 50 (27.5) 50 (19.6) 74 (19.3) 84 (15.7)
Black, n (%) 3 (50.0) 5 (38.5) 5 (35.7) 6 (33.3) 3 (20.0) 7 (29.2) 5 (14.7) 6 (12.8)
Other*, n (%) 5 (100.0) 5 (41.7) 5 (62.5) 6 (46.2) 5 (55.6) 3 (18.8) 6 (37.5) 8 (27.6)
30-day mortality rate, n (%) 56 (52.3) 71 (39.2) 44 (33.1) 50 (27.0) 42 (20.4) 44 (14.9) 66 (15.2) 55 (9.0)
By age group
65–74, n (%) 38 (46.9) 57 (38.3) 33 (31.4) 31 (22.8) 32 (18.6) 34 (14.4) 46 (13.2) 49 (10.1)
≥75, n (%) 18 (69.2) 13 (41.9) 11 (39.3) 18 (37.5) 10 (30.3) 10 (17.2) 19 (22.6) 4 (3.3)
By gender
Female, n (%) 16 (61.5) 25 (55.6) 10 (37.0) 14 (43.8) 11 (26.2) 7 (20.0) 8 (13.6) 12 (12.6)
Male, n (%) 40 (49.4) 46 (33.8) 34 (32.1) 36 (23.5) 31 (18.9) 37 (14.2) 58 (15.5) 43 (8.3)
By race
White, n (%) 50 (52.1) 62 (39.7) 36 (32.4) 41 (26.6) 36 (19.8) 37 (14.5) 58 (15.1) 49 (9.1)
Black, n (%) 2 (33.3) 3 (23.1) 4 (28.6) 3 (16.7) 3 (20.0) 5 (20.8) 4 (11.8) 1 (2.1)
Other*, n (%) 4 (80.0) 6 (50.0) 4 (50.0) 6 (46.2) 3 (33.3) 2 (12.5) 4 (25.0) 5 (17.2)
1-Year mortality rate, n (%) 74 (69.2) 121 (66.9) 72 (54.1) 93 (50.3) 82 (39.8) 90 (30.5) 135 (31.2)
By age group
65–74, n (%) 52 (64.2) 101 (67.8) 54 (51.4) 64 (47.1) 63 (36.6) 66 (28.0) 103 (29.6)
≥75, n (%) 22 (84.6) 19 (61.3) 18 (64.3) 28 (58.3) 19 (57.6) 23 (39.7) 31 (36.9)
By gender
Female, n (%) 20 (76.9) 32 (71.1) 15 (55.6) 20 (62.5) 13 (31.0) 8 (22.9) 17 (28.8)
Male, n (%) 54 (66.7) 89 (65.4) 57 (53.8) 73 (47.7) 69 (42.1) 82 (31.5) 118 (31.6)
By race
White, n (%) 64 (66.7) 106 (67.9) 61 (55.0) 75 (48.7) 72 (39.6) 77 (30.2) 121 (31.6)
Black, n (%) 5 (83.3) 7 (53.8) 5 (35.7) 10 (55.6) 5 (33.3) 8 (33.3) 8 (23.5)
Other*, n (%) 5 (100.0) 8 (66.7) 6 (75.0) 8 (61.5) 5 (55.6) 5 (31.3) 6 (37.5)
Length of stay
Overall LOS, days (SD) 23.6 (27.9) 29.8 (31.2) 31.0 (34.0) 30.6 (27.9) 33.5 (31.7) 32.1 (30.4) 24.6 (18.9) 27.3 (23.3)
Overall Pre-LOS, days 11.4 8.9 10.0 8.1 8.7 9.5 8.1 8.7
Overall Post-LOS, days 12.2 20.9 21.0 22.5 24.8 22.6 16.5 18.6
30-day readmission rate, n (%) 41 (38.1) 62 (34.1) 43 (32.0) 52 (27.9) 60 (29.3) 89 (30.2) 135 (31.1) 182 (29.7)
By age group
65–74, n (%) 29 (36.1) 49 (32.8) 36 (33.9) 42 (31.2) 50 (29.0) 69 (29.2) 107 (30.8) 136 (28.0)
≥75, n (%) 13 (50.0) 12 (38.9) 6 (23.1) 8 (17.2) 10 (31.8) 20 (34.8) 28 (32.8) 44 (36.3)
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2004 2005 2006 2007 2008 2009 2010 2011
By gender
Female, n (%) 7 (25.0) 19 (42.9) 13 (46.7) 5 (15.8) 14 (32.3) 14 (41.4) 20 (34.0) 27 (28.4)
Male, n (%) 33 (41.2) 44 (32.4) 30 (28.3) 46 (30.1) 47 (28.4) 74 (28.6) 115 (30.7) 155 (29.9)
By race
White, n (%) 34 (35.9) 56 (36.2) 39 (34.9) 39 (25.2) 53 (29.0) 76 (29.7) 118 (30.8) 159 (29.7)
Black, n (%) 4 (66.7) 5 (37.5) 14 (22.2) 8 (41.7) 6 (41.7) 10 (41.2) 13 (37.9) 15 (32.5)
Other*, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 6 (42.9) 0 (0.0) 4 (23.1) 3 (20.0) 7 (23.8)
Major discharge disposition
Home, n (%) 13 (12.1) 23 (12.7) 25 (18.8) 36 (19.5) 44 (21.4) 60 (20.3) 79 (18.2) 110 (18.0)
Home care, n (%) 15 (14.0) 30 (16.6) 24 (18.0) 41 (22.2) 64 (31.1) 95 (32.2) 133 (30.7) 213 (34.8)
Skilled nursing facility, n (%) 5 (4.7) 9 (5.0) 4 (3.0) 17 (9.2) 8 (3.9) 14 (4.7) 17 (3.9) 18 (2.9)
Rehospitalisation-related outcomes
1-year survival rate, n (%) 45 (42.0) 88 (49.0) 77 (58.0) 124 (67.0) 148 (72.0) 235 (80.0) 348 (80.0)
Rehospitalisation rate, n (%) 32 (70.0) 70 (80.0) 62 (80.0) 91 (70.0) 122 (80.0) 181 (80.0) 281 (80.0)
Average number of rehospitalisations 1.8 2.2 2.1 2.1 2.3 2.1 2.3
Rehospitalisation duration, mean days (SD) 30.2 (46.0) 21.5 (24.8) 22.2 (26.6) 22.8 (28.8) 27.8 (32.6) 20.2 (25.9) 20.8 (26.9)
CMS payment for index hospitalisations, $USD
Unadjusted $152 035 $180 160 $188 799 $187 797 $207 653 $220 188 $214 685 $225 697
Adjusted for inpatient hospital PPS $188 789 $216 566 $218 853 $210 534 $225 357 $230 657 $220 267 $225 697
CMS payment for rehospitalisations, $USD
Unadjusted $50 110 $40 680 $54 780 $43 460 $82 120 $56 480 $53 630
Adjusted for inpatient hospital PPS $60 647 $47 661 $61 891 $47 487 $86 863 $57 666 $53 630
*Includes Asian, Hispanic, North American Native or other not specified.
CMS, Centers for Medicare & Medicaid Services; LOS, length of stay; LVAD, left ventricular assist device; PPS, prospective payment system; USD, US Dollars.
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sthe index hospitalisation and rehospitalisations, CMS
payments were calculated using the average annual
change, a method that takes into account the ﬂuctua-
tions during the study period.
DISCUSSION
In this analysis we found an LVAD implantation rate
increase of nearly 491% with a sharp rise since 2008,
coincident with the approval of the Heart Mate II device
by the USA Food and Drug Administration.
2 Between
2010 and 2011 our results show 433 and 612 LVAD
implants consistent with the 5th Interagency Registry
for Mechanically Assisted Circulatory Support
(INTERMACS) report, which is not restricted to older
patients. They report 537 LVADs implanted as destin-
ation therapy in 2010 and 723 implantations in 2011.
Khazanie et al,
12 in another observational study, pub-
lished similar LVAD rates and higher transplantation
rates among Medicare beneﬁciaries likely due to a more
restrictive deﬁnition of our LVAD cohort.
12 Although we
cannot deﬁnitively state LVADs were implanted as destin-
ation therapy in our study, we limited our cohort to
patients with heart failure for more than 1 year who
received an LVAD. This cohort restriction was made in
order to capture the closest estimate of long-term LVADs
implanted. Only 108 patients in our cohort received
heart transplant mostly because a great part of our
population is older than the maximum recommended
age of 70 years for heart transplantation.
20 21 This is
much smaller than the 6th INTERMACS report in which
37% of LVAD patients receive heart transplant, suggest-
ing again that LVADs in our cohort were placed as des-
tination therapy.
22
The short-term and long-term mortality outcomes of
patients who received an LVAD improved signiﬁcantly. In
2011, we noted a survival rate of 70% at 1-year, which is
consistent with the reported survival of the 5th
INTERMACS report as well as the ﬁndings of Khazanie
et al,
12 and much improved from the 1-year survival in
2004 of 30%.
23 This observation has several possible
explanations. First, the reﬁnements in LVAD technology
resulted in smaller devices that facilitate less invasive pro-
cedures and may have produced fewer postoperative
complications, less need for replacement and more suc-
cessful recovery. Second, clinicians may have gained
Figure 2 (A) Observed relative and risk-adjusted annual changes for mortality rates and 30-day readmission rates comparing
2011 with 2004. (B) Point estimates with respect to changes of hospitalisation rates, 30-day, and 1-year mortality, comparing
2004 to 2011.
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Open Heartexperience not only with surgical techniques, but also
with optimising patient selection for LVAD procedures.
This may be quite relevant given the observed 56% rela-
tive decline in mortality rates among patients older than
75 years, which suggests that other factors, such as the
comorbidities or clinical status, may play a more import-
ant role in outcomes among elderly patients than age.
To better characterise aspects of the hospitalisations
related to LVAD implantations, we separated overall LOS
into pre-LOS and post-LOS. Our overall LOS of 27 days
is shorter than that reported by Khazanie et al who
found an average LOS of greater than 1 month. We
found a decreased pre-LOS and an increased post-LOS
when comparing to our own data, which is counter to
their ﬁndings. It is unclear why our estimates differed.
One explanation could be the difference in our two
cohorts. As mentioned above, we attempted to restrict
our cohort to non-emergent implants whereas Khazanie
et al included patients with codes for more acute condi-
tions such as cardiogenic shock. Our pre-LOS ﬂuctu-
ated, which precluded us from making inferences about
the slight overall increase. Post-LOS, however, consist-
ently increased. Given the lack of literature on post-
procedure quality of care or LOS, we can only speculate
that post-procedure time may have been used to opti-
mise postoperative care and care coordination post-
discharge, possibly affecting mortality rates such as the
30-day mortality rate. Longer post-LOS may contribute
to our observation of an increase in the number of
patients who were discharged to home and a decrease in
the number who were discharged to skilled nursing
facilities.
In order to assess patients’ inpatient needs 1 year after
LVAD implantation we calculated rehospitalisation rates,
which may reﬂect morbidity, as well as the total number
of days in the hospital, which may reﬂect quality of life.
Our results show that approximately 80% of patients are
rehospitalised within 1 year of implant. We found that
this estimate was stable over time and consistent with
prior observational study.
12 We also found that patients
spend an average of 20 days per year at the hospital.
Currently, the time spent in a hospital setting is approxi-
mately 30% less than in 2004. Despite the steady high-
rehospitalisation rates, the duration of total hospital stay
decreased over time suggesting improvements in quality
of life, consistent with a study that demonstrates
improvements in exercise performance and heart failure
severity post-LVADs.
24
New expensive technologies such as LVADs raise con-
cerns regarding resource allocation, with cost being a
potential limitation for its broader use.
25 Although, we
found that index LVAD hospitalisation remains expen-
sive over time, payments for rehospitalisations within the
ﬁrst year post-discharge declined despite increasing rates
of device implantation in older and sicker patients. We
speculate that our ﬁndings of decreasing costs of read-
missions may be due to a number of reasons including
less severe clinical reasons for rehospitalisation,
decreased number of days patients spend at the hospital
and improvements in outpatient follow-up. These ﬁnd-
ings underscore the importance of LVADs as a treatment
option despite the initial costs to the health system and
reinforce the need to improve rehospitalisation rates
among the elderly.
Our ﬁndings should be interpreted in light of several
limitations. The study is a descriptive report, including
only Medicare fee-for-service beneﬁciaries, limiting our
ability to generalise our results to patients younger than
65 years or outside of Medicare. However, approximately
80% of heart failure patients are older than 65 years
with limited therapeutic options in end-stage heart
failure,
26 making the elderly an important group in
which to examine issues related to the use of LVADs. In
addition, we cannot comment on trends in patients
enrolled in Medicare managed care programmes. As
more patients have migrated into Medicare managed
care programmes over time,
27 related changes in the
fee-for-service population may have affected the
observed trends. Our data cannot distinguish between
bridge to transplant and destination therapy, as we used
ICD-9-CM codes to deﬁne our cohort. Moreover, using
claims data, we cannot identify the model of device
implanted. Speciﬁcation of LVAD models placed is
beyond the scope of this study; however, during the
study period only HeartMate VE, HeartMate XVE and
HeartMate II were approved in the USA.
2352 8
Additionally, the use of Medicare claims data restricted
our ability to include some operation-speciﬁc informa-
tion in our risk-adjustment model. Finally, we deter-
mined the presence of comorbidities based on
administrative claims data rather than clinical conﬁrm-
ation; however, administrative codes have been shown to
be highly speciﬁc for cardiovascular diagnosis and risk
factors.
29
The rate of LVAD implantation in the USA increased
substantially from 2004 to 2011 among Medicare beneﬁ-
ciaries. More than 50% of the patients were discharged
to home after device placement and 80% were alive
1 year later. Costs are still increasing for the index hospi-
talisation but appear to be decreasing for rehospitalisa-
tions. Despite the improvement in outcomes the
absolute proportion of older patients with end-stage
heart failure who receive this technology remains low.
Author affiliations
1Center for Outcomes Research and Evaluation, Yale-New Haven Hospital,
New Haven, Connecticut, USA
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale
School of Medicine, New Haven, Connecticut, USA
3Section of General Internal Medicine, Department of Internal Medicine, Yale
School of Medicine, New Haven, Connecticut, USA
4Department of Health Care Policy, Harvard Medical School, Boston,
Massachusetts, USA
5Department of Chronic Disease Epidemiology, Yale School of Public Health,
New Haven, Connecticut, USA
6Division of Cardiology, Federal University of Sergipe, Aracaju, SE, Brazil
7Leon H. Charney Division of Cardiology, New York University School of
Medicine, New York, New York, USA
Lampropulos JF, Kim N, Wang Y, et al. Open Heart 2014;1:e000109. doi:10.1136/openhrt-2014-000109 9
Heart failure and cardiomyopathies8Section of Cardiac Surgery, Department of Surgery, Yale School of Medicine,
New Haven, Connecticut, USA
9Robert Wood Johnson Foundation Clinical Scholars Program, Department of
Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
10Department of Health Policy and Management, Yale School of Public Health,
New Haven, Connecticut, USA
Contributors JFL and HMK were involved in study concept and design. HMK
took part in acquisition of data. JFL, NK, YW, MMD and HMK were involved in
analysis and interpretation of data. JFL, NK and HMK took part in drafting of
the manuscript. JFL, NK, YW, MMD, JASB-F, JAD, DLD, AAM and HMK were
involved in critical revision of the manuscript for important intellectual
content. YW took part in statistical analysis. HMK obtained funding for the
study and also took part in administrative, technical or material support of the
study. NK and HMK supervised the study.
Funding This study was supported by grant 1U01HL105270-05 (Center for
Cardiovascular Outcomes Research at Yale University) from the National
Heart, Lung and Blood Institute in Bethesda, Maryland.
Previous Presentation: These data were presented, in part, at the Quality of
Care and Outcomes Research in Cardiovascular Disease and Stroke
Conference of the American Heart Association, 9–12 May 2012, in Atlanta,
Georgia and were presented, in part, at the Quality of Care and Outcomes
Research in Cardiovascular Disease and Stroke Conference of the American
Heart Association, 15–17 May 2013, in Baltimore, Maryland.
Competing interests HMK reports that he is the recipient of research grants
from Medtronic and from Johnson & Johnson, through Yale University, to
develop methods of clinical trial data sharing and is chair of a cardiac
scientific advisory board for UnitedHealth.
Ethics approval We obtained Institutional Review Board approval through the
Yale University Human Investigation Committee, which waived the
requirement for informed consent. Confidential data were protected through a
data use agreement with CMS.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left
ventricular assist device for end-stage heart failure. N Engl J Med
2001;345:1435–43.
2. US Food and Drug Administration. Department of Health and Human
Services. Device Approvals and Clearances. http://www.accessdata.
fda.gov/cdrh_docs/pdf6/p060040a.pdf (accessed 1 Oct 2013).
3. Centers for Medicare & Medicaid Services. Decision memo for
ventricular assist devices as destination therapy (CAG-00119N).
http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=79.
(accessed 12 Jul 2013).
4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline
update for the diagnosis and management of chronic heart failure in
the adult: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and
Management of Heart Failure). J Am Coll Cardiol 2005;46:e1–82.
5. National Heart, Lung and Blood Institute. Workshop, Meeting
Summaries, Scientific Reports. http://www.nhlbi.nih.gov/meetings/
workshops/nextgen-vads.htm. (accessed 12 Jul 2012).
6. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design
enhancements and its impact on device reliability. Eur J
Cardiothorac Surg 2004;25:958–63.
7. Pagani FD, Long JW, Dembitsky WP, et al. Improved mechanical
reliability of the HeartMate XVE left ventricular assist system. Ann
Thorac Surg 2006;82:1413–18.
8. Hernandez AF, Shea AM, Milano CA, et al. Long-term outcomes and
costs of ventricular assist devices among Medicare beneficiaries.
JAMA 2008;300:2398–406.
9. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-US Food
and Drug Administration-approval study with a continuous flow left
ventricular assist device as a bridge to heart transplantation: a
prospective study using the INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support). J Am Coll Cardiol
2011;57:1890–8.
10. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure
treated with continuous-flow left ventricular assist device. N Engl J
Med 2009;361:2241–51.
11. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical
circulatory support with a continuous-flow rotary left ventricular assist
device. J Am Coll Cardiol 2009;54:312–21.
12. Khazanie P, Hammill BG, Patel CB, et al. Trends in the use and
outcomes of ventricular assist devices among Medicare
beneficiaries, 2006–2011. J Am Coll Cardiol 2014;63:1395–404.
13. Centers for Medicare & Medicaid Services. http://www.medicare.gov/
sign-up-change-plans/medicare-health-plans/medicare-advantage-
plans/private-fee-for-service-plans.html (accessed 28 May 2014).
14. Eicheldinger C, Bonito A. More accurate racial and ethnic codes for
Medicare administrative data. Health Care Financ Rev
2008;29:27–42.
15. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims
model suitable for profiling hospital performance based on 30-day
mortality rates among patients with heart failure. Circulation
2006;113:1693–701.
16. Bratzler DW, Normand SL, Wang Y, et al. An administrative claims
model for profiling hospital 30-day mortality rates for pneumonia
patients. PLoS ONE 2011;6:e17401.
17. Keenan PS, Normand SL, Lin Z, et al. An administrative claims
measure suitable for profiling hospital performance on the basis of
30-day all-cause readmission rates among patients with heart failure.
Circ Cardiovasc Qual Outcomes 2008;1:29–37.
18. Krumholz HM, Lin Z, Drye EE, et al. An administrative claims
measure suitable for profiling hospital performance based on 30-day
all-cause readmission rates among patients with acute myocardial
infarction. Circ Cardiovasc Qual Outcomes 2011;4:243–52.
19. Lindenauer PK, Normand SL, Drye EE, et al. Development,
validation, and results of a measure of 30-day readmission
following hospitalization for pneumonia. J Hosp Med 2011;6:
142–50.
20. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis
and Management of Heart Failure in Adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines: developed in collaboration with the
International Society for Heart and Lung Transplantation. Circulation
2009;119:e391–479.
21. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke
statistics—2014 update: a report from the American Heart
Association. Circulation 2014;129:e28–292.
22. Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual
report: a 10,000-patient database. J Heart Lung Transplant
2014;33:555–64.
23. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual
report: risk factor analysis from more than 6,000 mechanical
circulatory support patients. J Heart Lung Transplant 2013;32:
141–56.
24. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left
ventricular assist device improves functional capacity and quality of
life of advanced heart failure patients. J Am Coll Cardiol
2010;55:1826–34.
25. Slaughter MS, Bostic R, Tong K, et al. Temporal changes in hospital
costs for left ventricular assist device implantation. J Card Surg
2011;26:535–41.
26. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke
statistics—2012 update: a report from the American Heart
Association. Circulation 2012;125:e2–220.
27. Kaiser Family Foundation. Medicare advantage 2010 data spotlight:
plan enrollment patterns and trends. http://www.kff.org/medicare/
upload/8080.pdf (accessed 12 Jul 2012).
28. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS annual
report: the evolution of destination therapy in the United States.
J Heart Lung Transplant 2011;30:115–23.
29. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM
codes for identifying cardiovascular and stroke risk factors. Med
Care 2005;43:480–5.
10 Lampropulos JF, Kim N, Wang Y, et al. Open Heart 2014;1:e000109. doi:10.1136/openhrt-2014-000109
Open Heart